Press Releases

Press Releases

 
Press Releases
Date Title and Summary View
May 15, 2017 - Vifor Pharma Commits to Exclusive Distribution of Vadadustat to Fresenius Medical Care North America for Use in its Dialysis Facilities and Invests $50 Million in Akebia at a Premium - - Additional Funds Support Vadadustat Global Development Program to Data − - Ake...
May 9, 2017 - Recent Collaboration Agreements Position Vadadustat Global Phase 3 Development Program for Success, Offer Strong Financial and Commercial Support, and Drive Significant Value Creation - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutica...
May 4, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that the company granted three newly hired employees o...
Apr 25, 2017 Maximizes Efficiency of Global Development and Commercialization Committed Capital and Potential Milestone Payments from Otsuka of up to $865 Million, Including $208 million or More in Upfront Payment and Development Funding, as well as Tiered, Double-Digit Royalties Total Committe...
Apr 7, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that the Company granted five newly hired employees op...
Mar 29, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that John P. Butler, President and Chief Executive Off...
Mar 28, 2017 -- Data Showed Vadadustat Increased Hemoglobin Levels and Improved Iron Mobilization When Compared to Placebo -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidne...
Mar 6, 2017 -- Company to Host Conference Call at 4:30 p.m. Eastern Time -- CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducibl...
Mar 1, 2017 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced that the Company will host a conference call on Monday, March ...
Feb 13, 2017 - Akebia Expands Pipeline and Leverages Expertise in HIF Biology with Access to Extensive Library of Compounds Addressing Multiple Therapeutic Areas - CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innov...
Page:
1
... NextLast
= add release to Briefcase